These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26564536)

  • 1. The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective.
    Scott C; Gardiner E; de Lucia A
    Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():17-22. PubMed ID: 26564536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Global TB Drug Facility: innovative global procurement.
    Kumaresan J; Smith I; Arnold V; Evans P
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):130-8. PubMed ID: 14974756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Global Drug Facility and its role in the market for tuberculosis drugs.
    Arinaminpathy N; Cordier-Lassalle T; Vijay A; Dye C
    Lancet; 2013 Oct; 382(9901):1373-9. PubMed ID: 23726162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Global Drug Facility: a unique, holistic and pioneering approach to drug procurement and management.
    Matiru R; Ryan T
    Bull World Health Organ; 2007 May; 85(5):348-53. PubMed ID: 17639218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric tuberculosis drug market: an insider perspective on challenges and solutions.
    Usherenko I; Basu Roy U; Mazlish S; Liu S; Benkoscki L; Coutts D; Epstein S; Qian M; Rafiq S; Scott C
    Int J Tuberc Lung Dis; 2015 Dec; 19 Suppl 1():23-31. PubMed ID: 26564537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024.
    Kohler S; Achar J; Mulder C; Sitali N; Paul N
    Global Health; 2024 Jun; 20(1):51. PubMed ID: 38918859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges.
    Gemal A; Keravec J; Menezes A; Trajman A
    BMC Public Health; 2013 Mar; 13():279. PubMed ID: 23537151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility.
    Lunte K; Cordier-Lassalle T; Keravec J
    Bull World Health Organ; 2015 Apr; 93(4):279-82. PubMed ID: 26229192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Roll-out of Child-friendly Fixed-dose Combination TB Formulations in High-TB-Burden Countries: A Case Study of STEP-TB.
    Faust L; Abdi K; Davis K; He C; Mehrotra C; Stibolt E
    J Epidemiol Glob Health; 2019 Sep; 9(3):210-216. PubMed ID: 31529940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed dose combinations for tuberculosis: Lessons learned from clinical, formulation and regulatory perspective.
    Panchagnula R; Agrawal S; Ashokraj Y; Varma M; Sateesh K; Bhardwaj V; Bedi S; Gulati I; Parmar J; Kaul CL; Blomberg B; Fourie B; Roscigno G; Wire R; Laing R; Evans P; Moore T
    Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):703-21. PubMed ID: 15632956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric drug-resistant tuberculosis: a global perspective: a global perspective.
    Reubenson G
    Paediatr Drugs; 2011 Dec; 13(6):349-55. PubMed ID: 21999648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of tuberculosis in children and new treatment options.
    Marais BJ; Schaaf HS; Donald PR
    Infect Disord Drug Targets; 2011 Apr; 11(2):144-56. PubMed ID: 21406050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality assurance in anti-tuberculosis drug procurement by the Stop TB Partnership-Global Drug Facility: Procedures, costs, time requirements, and comparison of assay and dissolution results by manufacturers and by external analysis.
    Hauk C; Schäfermann S; Martus P; Muzafarova N; Babaley M; Waning B; Heide L
    PLoS One; 2020; 15(12):e0243428. PubMed ID: 33270800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric TB: issues related to current and future treatment options.
    Marais BJ; Schaaf HS; Donald PR
    Future Microbiol; 2009 Aug; 4(6):661-75. PubMed ID: 19659423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How to cope with the global tuberculosis burden--experiences and perspectives for Japan's international cooperation].
    Ishikawa N
    Kekkaku; 2005 Feb; 80(2):89-94. PubMed ID: 15920981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tuberculosis in Asia].
    Kekkaku; 2002 Oct; 77(10):693-7. PubMed ID: 12440145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assessment survey of anti-tuberculosis drug management in Cambodia.
    Uchiyama Y; Mao TE; Okada K; Chay S; Kou Soum M; Leng C
    Int J Tuberc Lung Dis; 2006 Feb; 10(2):153-9. PubMed ID: 16499253
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.